Read, save, and print articles from the current issue


Chronological index


Compare all instruments
and software systems


Chronological index


Register Now and
On Demand

Home » Archive by Tags

Articles tagged with: Qiagen

CDC to use IGRAs for immigration TB screening

Feb. 28, 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will …

Qiagen to buy Stat-Dx

Feb. 20, 2018—Qiagen has entered into an agreement to acquire Stat-Dx, a developer of molecular diagnostics systems, for $147 million. …

Qiagen, DiaSorin partnership, 2/18

February 2018—Qiagen and DiaSorin announced a partnership in which Qiagen’s QuantiFeron-TB diagnostic test will be added to the menu of DiaSorin’s Liaison family of analyzers, enabling customers of both companies to process QuantiFeron-TB Gold Plus, a fourth-generation assay for latent tuberculosis detection, on Liaison platforms. QFT-Plus is the first assay from the QuantiFeron portfolio that is planned to be adapted for use on the Liaison systems, with additional assays under consideration.

Qiagen, Centogene join forces on rare disease testing, 1/18

January 2018—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight research and clinical testing solutions in rare genetic diseases. The collaboration includes the integration of Centogene’s CentoMD rare disease variant database into Qiagen’s bioinformatics offering to enhance test interpretation.

Qiagen, Centogene join forces on rare disease testing

Oct. 17, 2017—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight …

Qiagen joins Cancer-ID consortium, 8/17

August 2017—Qiagen has joined Cancer-ID, a public-private consortium of 36 partners from 13 countries that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

Qiagen launches JAK2 test

April 17, 2017—Qiagen launched its Ipsogen JAK2 RGQ PCR Kit, which was cleared by the Food and Drug Administration as …

Singulex, Qiagen to develop companion diagnostics, 4/17

April 2017—Singulex has entered into a strategic collaboration with Qiagen to develop companion diagnostics. Through the collaboration, Qiagen will have access to Singulex’s Single Molecule Counting (SMC) immunodiagnostic platform, adding immunoassay capabilities to Qiagen’s existing molecular testing services for the development of companion diagnostics.

TB test submitted for PMA, 3/17

March 2017—Qiagen announced it submitted its QuantiFeron-TB Gold Plus, the fourth generation of the modern blood test for detecting tuberculosis infection, for premarket approval by the Food and Drug Administration.

CALR mutation assay for MPN diagnosis, 2/17

February 2017—Qiagen announced the European launch of its CE-IVD marked calreticulin mutation assay to aid in establishing the diagnosis of myeloproliferative neoplasms. The ipsogen CALR RGQ PCR kit is intended for the detection of CALR mutations in genomic DNA from subjects suspected of myeloproliferative neoplasms. It enables identification of the two major CALR mutations, type 1 and type 2, and detects additional mutations in the CALR exon 9 region.